

L10 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:119949 CAPLUS Full-text

DN 140:267029

TI Miniaturization of Cell-Based  $\beta$ -Lactamase-Dependent FRET Assays to Ultra-High Throughput Formats to Identify Agonists of Human Liver X Receptors

AU Chin, Jayne; Adams, Alan D.; Bouffard, Aileen; Green, Ahren; Lacson, Raul G.; Smith, Todd; Fischer, Paul A.; Menke, John G.; Sparrow, Carl P.; Mitnaul, Lyndon J.

CS Department of Atherosclerosis and Endocrinology, Merck Research Laboratories, Rahway, NJ, USA

SO Assay and Drug Development Technologies (2003), 1(6), 777-787  
CODEN: ADDTAR; ISSN: 1540-658X

PB Mary Ann Liebert, Inc.

DT Journal

LA English


AB Activation of liver X receptors (LXRs) induces reverse cholesterol transport and increases high-d. lipoprotein cholesterol in vivo. Here, we describe novel, functional, homogeneous cell-based fluorescence resonance energy transfer assays for identifying agonists of LXRs using  $\beta$ -lactamase as the reporter gene. Stable Chinese hamster ovary cell lines expressing LXR $\alpha$ -GAL4 or LXR $\beta$ -GAL4 fusion proteins that regulate  $\beta$ -lactamase transcription from upstream 7 + UAS GAL4 DNA binding sequences were generated and characterized. Synthetic and natural ligands of LXR dose-dependently activated the expression of  $\beta$ -lactamase in a subtype-specific manner. These assays were used to demonstrate that a 1-pyridyl hydantoin small mol. LXR synthetic ligand specifically activates LXR $\alpha$  receptors. The  $\beta$ -lactamase assays were optimized for cell d., DMSO sensitivity, and time of agonist stimulation. Clonal LXR $\beta$ -GAL4- $\beta$ -lactamase cells were miniaturized into an ultra high throughput (3,456-well nanoplates) screening format.

IT 652992-38-6

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)  
(FRET assays were used to demonstrate that a 1-pyridyl hydantoin small mol. LXR synthetic ligand specifically activates LXR $\alpha$  receptors.)

RN 652992-38-6 CAPLUS

CN 2,4-Imidazolidinedione, 3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:101150 CAPLUS Full-text

DN 140:146124

TI Preparation of benzisoxazoles as LXR ligands for treating dyslipidemic conditions

IN Jones, A. Brian; Adams, Alan D.; Green, Ahren I.; Huang, Shaei Y.; Tse, Bruno; Gutteridge, Clare E.; Cheng, Yuan

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 134 pp.  
CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004011448	A1	20040205	WO 2003-US22807	20030721
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1534696	A1	20050601	EP 2003-771693	20030721
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005239769	A1	20051027	US 2005-522114	20050124
PRAI	US 2002-398716P	P	20020725		
	WO 2003-US22807	W	20030721		
OS	MARPAT	140:146124			
GI					

App's



I



II

AB The present invention relates to novel benzisoxazoles (shown as I; variables defined below; e.g. II) as LXR (nuclear oxysterol receptor) ligands and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed

levels of HDL cholesterol. Although the methods of preparation are not claimed, .aprx.60 example preps. of I and intermediates are included. For example, II was prepared from pyrrolidine-2,5-dione and 7-propyl-3-neopentyl-6-(3-bromopropoxy)-1,2-benzisoxazole in DMF in the presence of Cs<sub>2</sub>CO<sub>3</sub> at room temperature; 7-propyl-3-neopentyl-6-(3-bromopropoxy)-1,2-benzisoxazole was prepared from 6-hydroxy-7-propyl-3-neopentyl-1,2-benzisoxazole, 1,3-dibromopropane and Cs<sub>2</sub>CO<sub>3</sub> in DMF. The tested I have an IC<sub>50</sub> ≤ 2 μM for at least one of either the LXRα or LXRβ receptors employing the LXR radioligand competition scintillation proximity assays described. Examples of I tested for LXR transactivation have an EC<sub>50</sub> of <5,500 nM for at least one of LXRα or LXRβ receptor. Two examples of I were tested for their ability to increase cholesterol efflux from cultured human cells and the results are tabulated. For I: R<sub>1</sub> = CF<sub>3</sub>, CH<sub>2</sub>CMe<sub>3</sub>, Ph, C<sub>1</sub>-6 alkyl, and C<sub>1</sub>-2-alkylphenyl; R<sub>2</sub> = C<sub>1</sub>-6 alkyl, COOR<sub>3</sub>, CR<sub>3</sub>R<sub>4</sub>OR<sub>5</sub>, CR<sub>3</sub>R<sub>4</sub>SR<sub>5</sub>, and COR<sub>3</sub>; R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> = H, Ph, and C<sub>1</sub>-6 alkyl; Y is joined together with the N and the carbonyl C shown in I to which Y is resp. attached, to form a heterocyclic ring = 5-membered rings (2-oxopyrrolidin-1-yl, 2-oxoimidazolidin-1-yl, 4-oxoimidazolidin-1-yl, 2-oxothiazolidin-3-yl, 4-oxothiazolidin-1-yl), 6-membered rings (2-oxopiperidin-1-yl, 3-oxomorpholin-4-yl, 2-oxohexahydropyrimidin-1-yl, 6-oxo-1,2,3,6-tetrahydropyrimidin-1-yl, 2-oxohexahydropyrimidin-1-yl, 2-oxo-1,2,3,6-tetrahydropyrimidin-1-yl, 2-oxopiperazin-1-yl, 2-oxohexahydrotriazin-1-yl, 2-oxoazepan-1-yl), bicyclic heterocycles (phthalimido and related imides); Z = -C<sub>1</sub>-6alkyl-, -C<sub>1</sub>-6alkyl-O-, -C<sub>3</sub>-6cycloalkyl-, and -C<sub>3</sub>-6cycloalkyl-O-.


IT 652992-50-2P, 5-Methyl-5-(2-pyridyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione  
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(drug candidate, chromatog. resolution; preparation of benzisoxazoles as

LXR ligands for treating dyslipidemic conditions)

RN 652992-50-2 CAPLUS

CN 2,4-Imidazolidinedione, 5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)



546/272.1


514/238

IT 652992-51-3P, (S)-5-Methyl-5-(2-pyridyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione  
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of benzisoxazoles as LXR ligands for treating dyslipidemic conditions)

RN 652992-51-3 CAPLUS

CN 2,4-Imidazolidinedione, 5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-5-(2-pyridinyl)-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT   **652992-59-1P**, 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidin-2-one **652992-60-4P**, Methyl 2-[2-oxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidin-1-yl]propanoate **652992-82-0P**, 6-Phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione **652992-83-1P**, 5-Methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of benzisoxazoles as LXR ligands for treating dyslipidemic conditions)


RN   652992-59-1 CAPLUS

CN   2-Imidazolidinone, 1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI)   (CA INDEX NAME)



RN   652992-60-4 CAPLUS


CN   1-Imidazolidineacetic acid,  $\alpha$ -methyl-2-oxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-, methyl ester (9CI)  
(CA INDEX NAME)



RN   652992-82-0 CAPLUS


CN   2,4(1H,3H)-Pyrimidinedione, dihydro-6-phenyl-3-[[7-propyl-3-

(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX  
NAME)



RN 652992-83-1 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, dihydro-5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX  
NAME)



IT **652992-23-9P**, 1-[3-[[7-Propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]pyrrolidine-2,5-dione **652992-24-0P**,  
1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]pyrrolidine-2,5-dione **652992-25-1P**,  
2-[3-[[7-Propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1H-isoindole-1,3(2H)-dione **652992-26-2P**, 3,3-Dimethyl-1-[3-[[7-  
propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]pyrrolidine-2,5-dione **652992-27-3P**, 3-Methyl-3-phenyl-1-[3-[[7-  
propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]pyrrolidine-2,5-dione **652992-28-4P**, 3-[3-[[7-Propyl-3-(neopentyl)-1,2-benzisoxazol-6-  
yl]oxy]propyl]thiazolidine-2,4-dione **652992-29-5P**,  
3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-  
yl]oxy]propyl]thiazolidine-2,4-dione **652992-30-8P**,  
5,5-Dimethyl-3-[3-[[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-  
yl]oxy]propyl]thiazolidine-2,4-dione **652992-31-9P**,  
[2,4-Dioxo-3-[3-[[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-  
1,3-thiazolidin-5-yl]acetic acid **652992-33-1P**,  
3-[3-[[7-Propyl-3-(neopentyl)-1,2-benzisoxazol-6-  
yl]oxy]propyl]imidazolidine-2,4-dione **652992-34-2P**,  
3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-  
yl]oxy]propyl]imidazolidine-2,4-dione **652992-35-3P**,  
1-Methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-  
yl]oxy]propyl]imidazolidine-2,4-dione **652992-36-4P**,  
5-(R)-Methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-  
yl]oxy]propyl]imidazolidine-2,4-dione **652992-37-5P**,  
5,5-Dimethyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-  
yl]oxy]propyl]imidazolidine-2,4-dione **652992-38-6P**,  
1-(2-Pyridyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-  
yl]oxy]propyl]imidazolidine-2,4-dione **652992-41-1P**,  
5-Methyl-5-phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-

yl]oxy]propyl]imidazolidine-2,4-dione **652992-42-2P**,  
5-Methyl-5-phenyl-3-[3-[[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-  
yl]oxy]propyl]imidazolidine-2,4-dione **652992-43-3P**,  
5-Methyl-5-phenyl-3-[3-[[7-propyl-3-phenyl-1,2-benzisoxazol-6-  
yl]oxy]propyl]imidazolidine-2,4-dione **652992-44-4P**,  
5-Methyl-5-phenyl-3-[4-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-  
yl]oxy]butyl]imidazolidine-2,4-dione **652992-45-5P**,  
5-Methyl-5-(3-carboxyphenyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-  
benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-48-8P**  
, 5-Methyl-5-(4-pyridyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-  
benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-49-9P**  
, 5-Methyl-5-(3-pyridyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-  
benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-52-4P**  
, 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-  
(pyrimidin-2-yl)imidazolidine-2,4-dione **652992-53-5P**,  
3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-  
(pyrazin-2-yl)imidazolidine-2,4-dione **652992-54-6P**,  
3-[2,5-Dioxo-4-phenyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-  
6-yl]oxy]propyl]imidazolidin-4-yl]propanoic acid **652992-55-7P**,  
4-[5,5-Dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-  
benzisoxazol-6-yl]oxy]propyl]imidazolidin-1-yl]butanoic acid  
**652992-58-0P**, 5-[5,5-Dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-  
(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidin-1-  
yl]propanoic acid **652992-62-6P**, 1-[3-[[7-Propyl-3-  
(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione  
**652992-65-9P**, 5,5-Dimethyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-  
benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-70-6P**  
, 1-[trans-2-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-  
yl]oxy]cyclohexyl]methyl]dihydropyrimidine-2,6(1H,3H)-dione  
**652992-72-8P**, 1-[trans-2-[[7-Propyl-3-(trifluoromethyl)-1,2-  
benzisoxazol-6-yl]oxy]cyclopentyl]methyl]dihydropyrimidine-2,6(1H,3H)-  
dione **652992-78-4P**, 1-[4-[[7-Propyl-3-(trifluoromethyl)-1,2-  
benzisoxazol-6-yl]butyl]dihydropyrimidine-2,6(1H,3H)-dione  
**652992-80-8P**, 5-Phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-  
benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione  
**652992-85-3P**, 1,5-Dimethyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-  
benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione  
**652992-92-2P**, 1-Phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-  
benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione  
**652992-96-6P**, 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-  
6-yl]oxy]propyl]-1-pyridin-2-yldihydropyrimidine-2,4(1H,3H)-dione  
**652993-00-5P**, 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-  
6-yl]oxy]propyl]-5,6-dihydro-2H-1,2'-bipyrimidine-2,4(3H)-dione  
**652993-04-9P**, 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-  
6-yl]oxy]propyl]-5,6-dihydro-2H-1,5'-bipyrimidine-2,4(3H)-dione  
**652993-06-1P**, 1-[3-[[7-Propyl-3-(neopentyl)-1,2-benzisoxazol-6-  
yl]oxy]propyl]piperidin-2-one **652993-08-3P**, 1-[3-[[7-Propyl-3-  
(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]piperidin-2-one  
**652993-10-7P**, 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-  
6-yl]oxy]propyl]piperidin-2,6-dione **652993-13-0P**,  
1-[3-[[7-Propyl-3-phenyl-1,2-benzisoxazol-6-yl]oxy]propyl]piperidin-2,6-  
dione **652993-15-2P**, 4-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-  
benzisoxazol-6-yl]oxy]propyl]morpholine-3,5-dione **652993-17-4P**,  
1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-  
yl]oxy]propyl]piperazine-2,5-dione **652993-20-9P**,  
3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-  
1,3,5-triazinane-2,4-dione **652993-22-1P**, 3-[3-[[7-Propyl-3-  
phenyl-1,2-benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione


**652993-23-2P**, 6-Methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione  
**652993-24-3P**, 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]azepan-2-one **652993-25-4P**, 1-Phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzisoxazoles as LXR ligands for treating dyslipidemic conditions)


RN 652992-23-9 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-24-0 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-25-1 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-26-2 CAPLUS

CN 2,5-Pyrrolidinedione, 3,3-dimethyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-27-3 CAPLUS

CN 2,5-Pyrrolidinedione, 3-methyl-3-phenyl-1-[3-[(7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-28-4 CAPLUS

CN 2,4-Thiazolidinedione, 3-[3-[(3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-29-5 CAPLUS

CN 2,4-Thiazolidinedione, 3-[3-[(7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-30-8 CAPLUS

CN 2,4-Thiazolidinedione, 3-[3-[(3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl)oxy]propyl]-5,5-dimethyl- (9CI) (CA INDEX NAME)




RN 652992-31-9 CAPLUS

CN 5-Thiazolidineacetic acid, 3-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 652992-33-1 CAPLUS

CN 2,4-Imidazolidinedione, 3-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-34-2 CAPLUS

CN 2,4-Imidazolidinedione, 3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-35-3 CAPLUS


CN 2,4-Imidazolidinedione, 1-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-36-4 CAPLUS


CN 2,4-Imidazolidinedione, 5-methyl-3-[3-[(7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl)oxy]propyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 652992-37-5 CAPLUS

CN 2,4-Imidazolidinedione, 5,5-dimethyl-3-[3-[(7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-38-6 CAPLUS

CN 2,4-Imidazolidinedione, 3-[3-[(7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl)oxy]propyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 652992-41-1 CAPLUS

CN 2,4-Imidazolidinedione, 5-methyl-5-phenyl-3-[3-[(7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-42-2 CAPLUS

CN 2,4-Imidazolidinedione, 3-[3-[(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]-5-methyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 652992-43-3 CAPLUS

CN 2,4-Imidazolidinedione, 5-methyl-5-phenyl-3-[3-[(3-phenyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-44-4 CAPLUS

CN 2,4-Imidazolidinedione, 5-methyl-5-phenyl-3-[4-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]butyl]- (9CI) (CA INDEX NAME)




RN 652992-45-5 CAPLUS


CN Benzoic acid, 3-[4-methyl-2,5-dioxo-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-4-imidazolidinyl]- (9CI) (CA INDEX NAME)




RN 652992-48-8 CAPLUS  
 CN 2,4-Imidazolidinedione, 5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 652992-49-9 CAPLUS  
 CN 2,4-Imidazolidinedione, 5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 652992-52-4 CAPLUS  
 CN 2,4-Imidazolidinedione, 3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 652992-53-5 CAPLUS  
 CN 2,4-Imidazolidinedione, 3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-

benzisoxazol-6-yl]oxy]propyl]-1-pyrazinyl- (9CI) (CA INDEX NAME)




RN 652992-54-6 CAPLUS

CN 4-Imidazolidinepropanoic acid, 2,5-dioxo-4-phenyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-55-7 CAPLUS

CN 1-Imidazolidinebutanoic acid, 5,5-dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-58-0 CAPLUS

CN 1-Imidazolidinepentanoic acid, 5,5-dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-61-5 CAPLUS

CN 1-Imidazolidineacetic acid,  $\alpha$ -methyl-2-oxo-3-[3-[(7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-62-6 CAPLUS

CN 2,4-Imidazolidinedione, 1-[3-[(7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-65-9 CAPLUS


CN 2,4-Imidazolidinedione, 5,5-dimethyl-1-[3-[(7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-70-6 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, dihydro-3-[[1R,2S)-2-[(7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl)oxy]cyclohexyl]methyl]-, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 652992-72-8 CAPLUS


CN 2,4(1H,3H)-Pyrimidinedione, dihydro-3-[(1R,2S)-2-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]cyclopentyl]methyl]-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 652992-78-4 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, dihydro-3-[4-[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]butyl]- (9CI) (CA INDEX NAME)




RN 652992-80-8 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, dihydro-5-phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-85-3 CAPLUS


CN 2,4(1H,3H)-Pyrimidinedione, dihydro-1,5-dimethyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-92-2 CAPLUS  
 CN 2,4(1H,3H)-Pyrimidinedione, dihydro-1-phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-96-6 CAPLUS  
 CN 2,4(1H,3H)-Pyrimidinedione, dihydro-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 652993-00-5 CAPLUS  
 CN [1(2H),2'-Bipyrimidine]-2,4(3H)-dione, 5,6-dihydro-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-04-9 CAPLUS  
 CN [1(2H),5'-Bipyrimidine]-2,4(3H)-dione, 5,6-dihydro-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-06-1 CAPLUS  
 CN 2-Piperidinone, 1-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-08-3 CAPLUS  
 CN 2-Piperidinone, 1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-10-7 CAPLUS  
 CN 2,6-Piperidinedione, 1-[3-[(7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-13-0 CAPLUS  
 CN 2,6-Piperidinedione, 1-[3-[(3-phenyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-15-2 CAPLUS  
 CN 3,5-Morpholinedione, 4-[3-[(7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-17-4 CAPLUS  
 CN 2,5-Piperazinedione, 1-[3-[(7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652993-20-9 CAPLUS  
 CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-3-[3-[(7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-22-1 CAPLUS  
 CN 2,4(1H,3H)-Pyrimidinedione, dihydro-3-[3-[(3-phenyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-23-2 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, dihydro-6-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-24-3 CAPLUS

CN 2H-Azepin-2-one, hexahydro-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652993-25-4 CAPLUS

CN 2,4-Imidazolidinedione, 1-phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



IT 652992-57-9P, Ethyl 4-[5,5-dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidin-1-yl]butanoate 652992-64-8P, 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-3-(4-methoxybenzyl)imidazolidine-2,4-dione


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of benzisoxazoles as LXR ligands for treating dyslipidemic conditions)


RN 652992-57-9 CAPLUS

CN 1-Imidazolidinebutanoic acid, 5,5-dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 652992-64-8 CAPLUS

CN 2,4-Imidazolidinedione, 3-[(4-methoxyphenyl)methyl]-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RE.CNT 1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:314695 CAPLUS Full-text

DN 132:334473

TI Preparation of (carbamoylmethyl)pyrazinones as thrombin inhibitors

IN Sanderson, Philip E.; Lyle, Terry A.; Dorsey, Bruce D.; Stanton, Matthew G.; Staas, Donnette; Coburn, Craig; Naylor-Olsen, Adel M.; Morrissette, Matthew M.; Selnick, Harold G.; Nanterment, Philippe G.; Williams, Peter D.; Stauffer, Kenneth J.; Burgey, Christopher; Isaacs, Richard

PA Merck & Co., Inc., USA; Barrow, James, C.

SO PCT Int. Appl., 210 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000026211	A1	20000511	WO 1999-US25203	19991028
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2348734	AA	20000511	CA 1999-2348734	19991028
	EP 1124822	A1	20010822	EP 1999-958684	19991028
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AU 747776	B2	20020523	AU 2000-15997	19991028
	JP 2002528543	T2	20020903	JP 2000-579599	19991028
	US 6610692	B1	20030826	US 1999-429741	19991028
PRAI	US 1998-106417P	P	19981030		
	WO 1999-US25203	W	19991028		
OS	MARPAT	132:334473			
GI					



AB The (carbamoylmethyl)pyrazinones I [wherein b = NY1 or O; c = CY2 or N; d = CY3 or N; e-g = CY4 or N; Y1 and Y2 = independently H, (cyclo)alkyl, halogen, NH<sub>2</sub>, OH, or alkoxy; Y3 = H, (cyclo)alkyl, halogen, CN, NH<sub>2</sub>, or alkoxy; Y4 = independently H, alkyl, or halogen; W = H, R<sub>1</sub>, R<sub>1</sub>O<sub>2</sub>C, R<sub>1</sub>CO, R<sub>1</sub>SO<sub>2</sub>, R<sub>1</sub>(CH<sub>2</sub>)<sub>n</sub>NHCO, or (R<sub>1</sub>)<sub>2</sub>CH(CH<sub>2</sub>)<sub>n</sub>NHCO; n = 0-4; R<sub>1</sub> = H, (un)substituted (cycloalkyl)alkyl, alkoxyalkyl, difluoroalkyl, carboxyalkyl, Ph, naphthyl, heterocyclyl, etc.; X = H or halogen; R<sub>3</sub> = H, (cyclo)alkyl, halogen, (un)substituted Ph, acyl, heterocyclyl, CN, SMe, SOMe, or alkylsulfonyl] and its analogs were prepared I inhibited human  $\alpha$ -thrombin and are expected to be useful as blood platelet aggregation inhibitors, thrombus formation


inhibitors, anticoagulants, and thrombolytics. Thus, 3-(2-phenylethylamino)-6-methyl-1-carboxymethylpyrazinone was amidated by 5-aminomethylindole in DMF in the presence of HOBT, EDC, and TEA to yield the (indolylmethylcarbamoylmethyl) pyrazinone II, which showed thrombin inhibitory activity with a Ki of  $\leq$  20 nM.

IT 267874-82-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(target compound; preparation of  
(heterocyclymethylcarbamoylmethyl)pyrazinone  
s as thrombin inhibitors)

RN 267874-82-8 CAPLUS

CN 1(2H)-Pyrazineacetamide, 6-methyl-N-[(3-methyl-1,2-benzisoxazol-5-yl)methyl]-2-oxo-3-[(2-(2-pyridinyl)ethyl)amino]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1989:614472 CAPLUS Full-text

DN 111:214472

TI Preparation of 3-piperidinyl-1,2-benzisoxazoles as psychotic drugs

IN Antoku, Fujio; Yoshigi, Mayumi; Saji, Ikutaro; Ishizumi, Kikuo

PA Sumitomo Pharmaceuticals Co., Ltd., Japan

SO Eur. Pat. Appl., 43 pp.







CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 314098	A2	19890503	EP 1988-117836	19881026
	EP 314098	A3	19900103		
	EP 314098	B1	19930804		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE JP 01199967 CA 1335289 US 4937249 AT 92489 ES 2059468	A2	19890811	JP 1988-266754	19881021
		A1	19950418	CA 1988-581028	19881024
		A	19900626	US 1988-262575	19881025
		E	19930815	AT 1988-117836	19881026
		T3	19941116	ES 1988-117836	19881026
PRAI	JP 1987-271462	A	19871026		
	EP 1988-117836	A	19881026		
OS	MARPAT 111:214472				
GI					



AB The title compds. (I; A = CO, SO<sub>2</sub>; when A = CO, B = Q1-Q5; when A = SO<sub>2</sub>, B = 1,2-phenylene; R1 = R2 = H; or either one of R1, R2 = H, the other = OH, C1-5 alkyl, C2-6 alkanoyloxy; R1R2 = O; E = O, CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>; F = CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>; R3-R8 = H, C1-5 alkyl; R9-R12 = C1-5 alkyl; R11R12 = C3-5 alkylene; n = 0-2; W = C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-6 hydroxyalkylene; G = H, C1-5 alkyl, C1-5 alkoxy, halo, HO) were prepared as psychotic drugs useful as highly selective neuroleptics, active also as analgesics, allergy inhibitors, and cardiovascular agents. A mixture of N-(4-bromobutyl)cyclohexane-1,2-dicarboximide, 3-(4-piperidinyl)-6-fluoro-1,2-benzisoxazole, K<sub>2</sub>CO<sub>3</sub>, and KI in DMF was heated 11 h at 90-100° to give 72.8% N-[4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidinyl]butyl]cyclohexane-1,2-dicarboximide (II). In a test for neuroleptic activity against pos. symptoms, II suppressed the climbing behavior in mice induced by apomorphine with an ED<sub>50</sub> of 0.92 mg/kg after 1 h, vs. 1.8 and 9.4 mg/kg for chlorpromazine and tiaspirone, resp.


IT 123547-84-2P 123547-85-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of, as antipsychotic)

RN 123547-84-2 CAPLUS


CN 1H-Isoindole-1,3(2H)-dione, hexahydro-2-[4-[4-(6-methyl-1,2-benzisoxazol-3-yl)-1-piperidinyl]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 123547-85-3 CAPLUS

CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, hexahydro-2-[4-[4-(6-methyl-1,2-benzisoxazol-3-yl)-1-piperidinyl]butyl]-, monohydrochloride,  
(3a $\alpha$ ,4 $\beta$ ,7 $\beta$ ,7a $\alpha$ )- (9CI) (CA INDEX NAME)

Relative stereochemistry.





● HCl

=> d 12; d 17; d his; log y

L2 HAS NO ANSWERS

L1 STR





Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

L7 HAS NO ANSWERS

L6 STR



G1 Cb,Ak

Structure attributes must be viewed using STN Express query preparation.

L7 QUE ABB=ON PLU=ON L6

(FILE 'HOME' ENTERED AT 09:59:44 ON 10 NOV 2005)

FILE 'REGISTRY' ENTERED AT 09:59:53 ON 10 NOV 2005

L1 STRUCTURE uploaded

L2 QUE L1

L3 2 S L2

L4 76 S L2 FUL

FILE 'CAPLUS' ENTERED AT 10:00:16 ON 10 NOV 2005

L5 12 S L4

FILE 'REGISTRY' ENTERED AT 10:00:23 ON 10 NOV 2005

L6 STRUCTURE uploaded

L7 QUE L6

L8 2 S L7 SAM SUB=L4

L9 63 S L7 FUL SUB=L4

FILE 'CAPLUS' ENTERED AT 10:01:37 ON 10 NOV 2005

L10 4 S L9

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
----------------------	------------------	---------------

FULL ESTIMATED COST	20.21	221.11
---------------------	-------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
--	------------------	---------------

CA SUBSCRIBER PRICE	-2.92	-2.92
---------------------	-------	-------

STN INTERNATIONAL LOGOFF AT 10:02:26 ON 10 NOV 2005